Pfiz­er in­fus­es $200M in­to CStone, scor­ing a sec­ond PD-L1 and out­lin­ing a sprawl­ing Chi­na pact

Pfiz­er has en­gi­neered a wide-rang­ing Chi­na pact with CStone, with an ini­tial $200 mil­lion in­vest­ment and a li­cense to the late-stage PD-L1 drug to get …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.